CD99作为白血病潜在治疗靶点的研究进展  

Progress of CD99 as a potential therapeutic target for leukemia

作　　者：李慧 朱鸣[1] 冯磊[1] 肖毅[2] Li Hui;Zhu Ming;Feng Lei;Xiao Yi(Department of Hematology,Tianyou Hospital,Wuhan University of Science and Technology,Wuhan 430000,China;Department of Hematology,Tongji Hospital,Huazhong University of Science and Technology,Wuhan 430000,China)

机构地区：[1]武汉科技大学附属天佑医院血液内科,武汉430000 [2]华中科技大学同济医学院附属同济医院血液内科,武汉430000

出　　处：《白血病．淋巴瘤》2023年第11期694-697,共4页Journal of Leukemia & Lymphoma

基　　金：武汉市科技局知识创新专项曙光计划(2022020801020313);湖北省教育厅科学研究计划中青年人才项目(Q20211113)。

摘　　要：CD99基因编码一种跨膜蛋白,参与细胞分化、黏附、迁移和蛋白质运输。CD99在绝大多数正常组织细胞中普遍表达较低,在骨髓和淋巴系造血细胞表面均有差异表达。现就CD99在血液疾病中的研究进展进行综述,探索CD99在髓系和淋巴细胞白血病中的作用及CD99作为血液恶性肿瘤治疗靶点的意义。CD99 gene encodes a transmembrane protein and participates in cell differentiation,adhesion,migration and protein transport.The expression of CD99 is generally low in most normal tissues and cells,and CD99 is differentially expressed in bone marrow and the surface of lymphatic hematopoietic cells.This article reviews the research progress of CD99 in hematological diseases,explores the role of CD99 in myeloid and lymphocytic leukemia,and the significance of CD99 as a therapeutic target for hematological malignancies.

关 键 词：CD99 血液肿瘤 分子靶向治疗 嵌合抗原受体T细胞 免疫疗法 

分 类 号：R733.7[医药卫生—肿瘤]